Mineralys Therapeutics (MLYS) EBITDA (2022 - 2026)
Mineralys Therapeutics (MLYS) posted EBITDA of -$45.3 million for Q1 2026, down 18.44% sequentially from -$38.3 million in Q4 2025, and down 2.01% YoY from -$46.3 million in Q1 2025.
Mineralys Therapeutics (MLYS) EBITDA (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported EBITDA for 5 years, with the latest figure at -$45.3 million in Q1 2026.
- Quarterly EBITDA fell 2.01% year-over-year to -$45.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$171.5 million (up 14.88% YoY) and the FY2025 annual result came in at -$170.6 million, up 11.33% from the prior year.
- EBITDA slipped to -$45.3 million in Q1 2026 per MLYS's latest filing, from -$38.3 million in the prior quarter.
- Over five years, EBITDA peaked at -$6.5 million in Q2 2022 and troughed at -$60.1 million in Q3 2024.
- A 5-year average of -$30.9 million and a median of -$35.4 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2025: EBITDA sank 253.94% in 2023, then jumped 31.57% in 2025.
- Over 5 years, EBITDA stood at -$10.0 million in 2022, then sank by 176.89% to -$27.7 million in 2023, then plunged by 86.81% to -$51.8 million in 2024, then rose by 26.05% to -$38.3 million in 2025, then declined by 18.44% to -$45.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$45.3 million, -$38.3 million, and -$41.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | -246.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -246.04 Mn |
| Mar 31, 2026 | -45.34 Mn |
| Dec 31, 2025 | -38.28 Mn |
| Sep 30, 2025 | -41.13 Mn |
| Jun 30, 2025 | -46.75 Mn |
| Mar 31, 2025 | -44.45 Mn |
| Dec 31, 2024 | -51.77 Mn |
| Sep 30, 2024 | -60.11 Mn |
| Jun 30, 2024 | -45.17 Mn |
| Mar 31, 2024 | -35.36 Mn |
| Dec 31, 2023 | -27.71 Mn |
| Sep 30, 2023 | -26.27 Mn |
| Jun 30, 2023 | -15.74 Mn |
| Mar 31, 2023 | -14.94 Mn |
| Dec 31, 2022 | -10.01 Mn |
| Sep 30, 2022 | -7.42 Mn |
| Jun 30, 2022 | -6.48 Mn |
| Mar 31, 2022 | -7.57 Mn |